耐甲氧西林金黄色葡萄球菌(MRSA)鼻腔筛查排除MRSA肺炎的临床效用:一项具抗菌药物管理意义的诊断性Meta分析
该Meta分析检索PubMed和EMBASE至2016年11月,纳入22项研究共5163例患者,评估MRSA鼻腔筛查诊断MRSA肺炎的价值。汇总灵敏度70.9%、特异度90.3%;在10%患病率下阳性预测值44.8%、阴性预测值96.5%。社区获得性肺炎和医疗保健相关肺炎的汇总灵敏度和特异度分别为85%和92.1%。
要点
- MRSA鼻腔筛查排除MRSA肺炎的汇总特异度为90.3%,阴性预测值为96.5%。
- 社区获得性肺炎和医疗保健相关肺炎的汇总灵敏度85%、特异度92.1%。
- 作者认为MRSA鼻腔筛查是抗菌药物管理中有价值的工具。
核心结论
- MRSA鼻腔筛查排除MRSA肺炎具有高特异度和阴性预测值,尤其在社区获得性肺炎和医疗保健相关肺炎病例中。
- 基于阴性预测值,MRSA鼻腔筛查是抗菌药物管理中有价值的工具,可用于简化经验性抗生素治疗,尤其适用于未定植MRSA的肺炎患者。
研究设计与样本
- 诊断性Meta分析,检索PubMed和EMBASE自建库至2016年11月的英文研究,评估MRSA鼻腔筛查与MRSA肺炎发生。
- 共纳入22项研究,合计5163例患者。
- 采用双变量随机效应模型估计汇总灵敏度、特异度、阳性预测值和阴性预测值。
主要发现
- MRSA鼻腔筛查诊断所有类型MRSA肺炎的汇总灵敏度为70.9%,特异度为90.3%。
- 在潜在MRSA肺炎患病率10%时,计算阳性预测值为44.8%,阴性预测值为96.5%。
- MRSA社区获得性肺炎和医疗保健相关肺炎的汇总灵敏度为85%,特异度为92.1%;阳性预测值和阴性预测值分别增至56.8%和98.1%。
- MRSA呼吸机相关性肺炎的灵敏度为40.3%,特异度为93.7%,阳性预测值为35.7%,阴性预测值为94.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent literature has highlighted methicillin-resistant Staphylococcus aureus (MRSA) nasal screening as a possible antimicrobial stewardship program tool for avoiding unnecessary empiric MRSA therapy for pneumonia, yet current guidelines recommend MRSA therapy based on risk factors. The objective of this meta-analysis was to evaluate the diagnostic value of MRSA nasal screening in MRSA pneumonia. METHODS: PubMed and EMBASE were searched from inception to November 2016 for English studies evaluating MRSA nasal screening and development of MRSA pneumonia. Data analysis was performed using a bivariate random-effects model to estimate pooled sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). RESULTS: Twenty-two studies, comprising 5163 patients, met our inclusion criteria. The pooled sensitivity and specificity of MRSA nares screen for all MRSA pneumonia types were 70.9% and 90.3%, respectively. With a 10% prevalence of potential MRSA pneumonia, the calculated PPV was 44.8%, and the NPV was 96.5%. The pooled sensitivity and specificity for MRSA community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) were 85% and 92.1%, respectively. For CAP and HCAP both the PPV and NPV increased, to 56.8% and 98.1%, respectively. In comparison, for MRSA ventilated-associated pneumonia, the sensitivity, specificity, PPV, and NPV were 40.3%, 93.7%, 35.7%, and 94.8%, respectively. CONCLUSION: Nares screening for MRSA had a high specificity and NPV for ruling out MRSA pneumonia, particularly in cases of CAP/HCAP. Based on the NPV, MRSA nares screening is a valuable tool for AMS to streamline empiric antibiotic therapy, especially among patients with pneumonia who are not colonized with MRSA.
引用
- Parente DM, Cunha CB, Mylonakis E, et al. The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications. Clin Infect Dis. 2018. PMID: 29340593. doi:10.1093/cid/ciy024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。